Kodiak Sciences sets IPO pricing terms
Palo Alto, California-based Kodiak Sciences Inc, a biopharmaceutical company focused on treating chronic retinal diseases, has priced its IPO of 9 million shares at between $13 and $15 per share. Kodiak will list the stock on the NASDAQ under the ticker symbol "KOD." Morgan Stanley and BofA Merrill Lynch are the lead underwriters. Kodiak is backed by ArrowMark Partners and Perceptive Advisors, according to Crunchbase.
25 September 2018•2 mins read
